NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: ABVC BioPharma's BioKey Facility Expansion and Operational Capabilities
TL;DR
ABVC BioPharma's expanded Silicon Valley facility offers partners a competitive edge with fully domestic development, reducing cross-border complexities and enhancing supply-chain resilience.
BioKey's 28,176-square-foot facility integrates formulation development, analytical testing, quality operations, and pilot-scale preparation within a single U.S.-based location supporting multiple product types.
ABVC's facility expansion will create up to 1,000 jobs by 2030 while developing pharmaceutical and functional food products that improve health outcomes globally.
ABVC BioPharma's Silicon Valley facility develops everything from botanical products to controlled-release pharmaceuticals in a single integrated location spanning over 28,000 square feet.
Found this article helpful?
Share it with your network and spread the knowledge!
ABVC BioPharma announced that its subsidiary BioKey has strengthened operations at its 28,176-square-foot pharmaceutical development and manufacturing facility in Silicon Valley, enhancing its multi-product capabilities and expansion outlook supporting up to 1,000 jobs by 2030.
BioKey's facility is located in Fremont, California, in Silicon Valley, and spans 28,176 square feet with over 12,054 square feet of expansion-ready space.
The facility supports pharmaceutical formulations, botanical and plant-based products, controlled-release and specialized solid-oral dosage forms, and functional food and nutraceutical products.
A fully domestic development pathway reduces cross-border complexities and enhances supply-chain resilience, which are attractive to potential partners seeking reliable manufacturing and development capabilities.
BioKey provides formulation development, process development and pilot-scale preparation, analytical testing, stability studies, quality documentation, technical and regulatory support for U.S. and international submissions, and cross-functional support for technology-transfer programs.
By 2030, ABVC anticipates that BioKey's expanded activities and partner-supported programs will support up to 1,000 jobs across formulation, analytical development, quality operations, regulatory support, documentation, data management, and supply-chain coordination.
The facility serves as a central component of ABVC's global chemistry, manufacturing, and controls (CMC) and U.S.-Asia development strategy, enabling multiple development programs to be executed in parallel within a single integrated U.S. location.
The facility has over 12,054 square feet of expansion-ready space that can accommodate additional analytical capacity, expanded development and production workflows, technology-transfer and documentation centers, and functional food and clinical material preparation zones.
Dr. Uttam Patil, ABVC's Chief Executive Officer, stated that BioKey is an essential pillar of ABVC's global development strategy, providing a fully U.S.-based platform capable of supporting multiple pharmaceutical, botanical, and functional food programs.
Curated from NewMediaWire
